Human apoA-I[Lys107del] mutation affects lipid surface behavior of apoA-I and its ability to form large nascent HDL. 2023

Irina N Gorshkova, and Nathan L Meyers, and Haya Herscovitz, and Xiaohu Mei, and David Atkinson
Department of Physiology and Biophysics, Boston University School of Medicine, Boston, MA, USA. Electronic address: igorshko@bu.edu.

Population studies have found that a natural human apoA-I variant, apoA-I[K107del], is strongly associated with low HDL-C but normal plasma apoA-I levels. We aimed to reveal properties of this variant that contribute to its unusual phenotype associated with atherosclerosis. Our oil-drop tensiometry studies revealed that compared to WT, recombinant apoA-I[K107del] adsorbed to surfaces of POPC-coated triolein drops at faster rates, remodeled the surfaces to a greater extent, and was ejected from the surfaces at higher surface pressures on compression of the lipid drops. These properties may drive increased binding of apoA-I[K107del] to and its better retention on large triglyceride-rich lipoproteins, thereby increasing the variant's content on these lipoproteins. While K107del did not affect apoA-I capacity to promote ABCA1-mediated cholesterol efflux from J774 cells, it impaired the biogenesis of large nascent HDL particles resulting in the formation of predominantly smaller nascent HDL. Size-exclusion chromatography of spontaneously reconstituted 1,2-dimyristoylphosphatidylcholine-apoA-I complexes showed that apoA-I[K107del] had a hampered ability to form larger complexes but formed efficiently smaller-sized complexes. CD analysis revealed a reduced ability of apoA-I[K107del] to increase α-helical structure on binding to 1,2-dimyristoylphosphatidylcholine or in the presence of trifluoroethanol. This property may hinder the formation of large apoA-I[K107del]-containing discoidal and spherical HDL but not smaller HDL. Both factors, the increased content of apoA-I[K107del] on triglyceride-rich lipoproteins and the impaired ability of the variant to stabilize large HDL particles resulting in reduced lipid:protein ratios in HDL, may contribute to normal plasma apoA-I levels along with low HDL-C and increased risk for CVD.

UI MeSH Term Description Entries
D008074 Lipoproteins Lipid-protein complexes involved in the transportation and metabolism of lipids in the body. They are spherical particles consisting of a hydrophobic core of TRIGLYCERIDES and CHOLESTEROL ESTERS surrounded by a layer of hydrophilic free CHOLESTEROL; PHOSPHOLIPIDS; and APOLIPOPROTEINS. Lipoproteins are classified by their varying buoyant density and sizes. Circulating Lipoproteins,Lipoprotein,Lipoproteins, Circulating
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D004134 Dimyristoylphosphatidylcholine A synthetic phospholipid used in liposomes and lipid bilayers for the study of biological membranes. Dimyristoyllecithin,1,2-Dimyristoyl-glycero-3-phosphorylcholine,1,2-Ditetradecanoyl-glycero-3-phosphocholine,1,2-Ditetradecyl-glycero-3-phosphocholine,DMCP,DMPC,1,2 Dimyristoyl glycero 3 phosphorylcholine,1,2 Ditetradecanoyl glycero 3 phosphocholine,1,2 Ditetradecyl glycero 3 phosphocholine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014280 Triglycerides An ester formed from GLYCEROL and three fatty acid groups. Triacylglycerol,Triacylglycerols,Triglyceride
D016632 Apolipoprotein A-I The most abundant protein component of HIGH DENSITY LIPOPROTEINS or HDL. This protein serves as an acceptor for CHOLESTEROL released from cells thus promoting efflux of cholesterol to HDL then to the LIVER for excretion from the body (reverse cholesterol transport). It also acts as a cofactor for LECITHIN CHOLESTEROL ACYLTRANSFERASE that forms CHOLESTEROL ESTERS on the HDL particles. Mutations of this gene APOA1 cause HDL deficiency, such as in FAMILIAL ALPHA LIPOPROTEIN DEFICIENCY DISEASE and in some patients with TANGIER DISEASE. Apo A-I,Apo A-1,Apo A-I Isoproteins,Apo A1,Apo AI,ApoA-1,ApoA-I,Apolipoprotein A-1,Apolipoprotein A-I Isoprotein-2,Apolipoprotein A-I Isoprotein-4,Apolipoprotein A-I Isoproteins,Apolipoprotein A1,Apolipoprotein AI,Apolipoprotein AI Propeptide,Pro-Apo A-I,Pro-Apolipoprotein A-I,Proapolipoprotein AI,Apo A I Isoproteins,Apolipoprotein A 1,Apolipoprotein A I,Apolipoprotein A I Isoprotein 2,Apolipoprotein A I Isoprotein 4,Apolipoprotein A I Isoproteins,Pro Apo A I,Pro Apolipoprotein A I
D053442 High-Density Lipoproteins, Pre-beta A highly dense subclass of the high-density lipoproteins, with particle sizes below 7 nm. They are also known as nascent HDL, composed of a few APOLIPOPROTEIN A-I molecules which are complexed with PHOSPHOLIPIDS. The lipid-poor pre-beta-HDL particles serve as progenitors of HDL3 and then HDL2 after absorption of free cholesterol from cell membranes, cholesterol esterification, and acquisition of apolipoproteins A-II, Cs, and E. Pre-beta-HDL initiate the reverse cholesterol transport process from cells to liver. High-Density Lipoprotein, Pre-beta1,Lipoprotein, Pre-beta HDL,Nascent HDL,Pre-beta HDL,Pre-beta High-Density Lipoprotein,Pre-beta1 HDL,Pre-beta1 High-Density Lipoprotein,PreBeta-HDL,HDL Lipoprotein, Pre-beta,HDL, Nascent,HDL, Pre-beta,HDL, Pre-beta1,High Density Lipoprotein, Pre beta1,High Density Lipoproteins, Pre beta,High-Density Lipoprotein, Pre-beta,Lipoprotein, Pre beta HDL,Lipoproteins, Pre-beta High-Density,Pre beta HDL,Pre beta High Density Lipoprotein,Pre beta1 HDL,Pre beta1 High Density Lipoprotein,Pre-beta HDL Lipoprotein,Pre-beta High-Density Lipoproteins,PreBeta HDL

Related Publications

Irina N Gorshkova, and Nathan L Meyers, and Haya Herscovitz, and Xiaohu Mei, and David Atkinson
January 2002, Journal of lipid research,
Irina N Gorshkova, and Nathan L Meyers, and Haya Herscovitz, and Xiaohu Mei, and David Atkinson
January 2019, Journal of lipid research,
Irina N Gorshkova, and Nathan L Meyers, and Haya Herscovitz, and Xiaohu Mei, and David Atkinson
April 2006, Journal of lipid research,
Irina N Gorshkova, and Nathan L Meyers, and Haya Herscovitz, and Xiaohu Mei, and David Atkinson
November 2008, Journal of lipid research,
Irina N Gorshkova, and Nathan L Meyers, and Haya Herscovitz, and Xiaohu Mei, and David Atkinson
July 2011, Journal of lipid research,
Irina N Gorshkova, and Nathan L Meyers, and Haya Herscovitz, and Xiaohu Mei, and David Atkinson
April 2016, The Journal of clinical endocrinology and metabolism,
Irina N Gorshkova, and Nathan L Meyers, and Haya Herscovitz, and Xiaohu Mei, and David Atkinson
October 2008, Arteriosclerosis, thrombosis, and vascular biology,
Irina N Gorshkova, and Nathan L Meyers, and Haya Herscovitz, and Xiaohu Mei, and David Atkinson
October 1999, Journal of lipid research,
Irina N Gorshkova, and Nathan L Meyers, and Haya Herscovitz, and Xiaohu Mei, and David Atkinson
July 2002, Arteriosclerosis, thrombosis, and vascular biology,
Irina N Gorshkova, and Nathan L Meyers, and Haya Herscovitz, and Xiaohu Mei, and David Atkinson
October 2018, Journal of personalized medicine,
Copied contents to your clipboard!